Ticlopidine HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318871

CAS#: 53885-35-1 (HCl)

Description: Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic thrombocytopenic purpura it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.


Chemical Structure

img
Ticlopidine HCl
CAS# 53885-35-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 318871
Name: Ticlopidine HCl
CAS#: 53885-35-1 (HCl)
Chemical Formula: C14H15Cl2NS
Exact Mass:
Molecular Weight: 300.241
Elemental Analysis: C, 56.01; H, 5.04; Cl, 23.61; N, 4.67; S, 10.68

Size Price Shipping out time Quantity
1g USD 90 2 Weeks
2g USD 150 2 Weeks
5g USD 250 2 Weeks
10g USD 450 2 Weeks
20g USD 750 2 Weeks
50g USD 1450 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

Ticlopidine HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Related CAS #: CAS#53885-35-1 (HCl)   55142-85-3 (free base).  

Synonym: 53 32C; 53-32C; 5332C; Ticlodix; Ticlodone; Ticlopidine; Ticlopidine HCl; trade name Ticlid; Ticlopidine Hydrochloride;

IUPAC/Chemical Name: 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride

InChi Key: MTKNGOHFNXIVOS-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H

SMILES Code: C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl.Cl

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 300.241 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM, Barnato SE, Winters JL, Cursio JF, Weiss I, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen H, Chen F, Armstrong JM, Raisch DW, Bennett CL. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov;38(8):845-53. doi: 10.1055/s-0032-1328894. Epub 2012 Oct 30. Review. PubMed PMID: 23111862; PubMed Central PMCID: PMC3804561.

2: Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov;38(8):905-7. doi: 10.1055/s-0032-1328890. Epub 2012 Oct 21. Review. PubMed PMID: 23086541; PubMed Central PMCID: PMC3947536.

3: Kaul U, Mansoor AH. Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey. Indian Heart J. 2012 Jan-Feb;64(1):54-9. doi: 10.1016/S0019-4832(12)60012-1. Epub 2012 Mar 26. Review. PubMed PMID: 22572427; PubMed Central PMCID: PMC3861274.

4: Yokoyama T, Usui T, Kiyama K, Nakashima R, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T. Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men. Mod Rheumatol. 2010 Aug;20(4):405-9. doi: 10.1007/s10165-010-0289-3. Epub 2010 Apr 8. Review. PubMed PMID: 20376687.

5: Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Epub 2009 Nov 30. Review. Erratum in: J Clin Pharmacol. 2010 Apr;50(4):483. PubMed PMID: 19948947.

6: Fettser DV, Preobrazhenskiĭ DV, Batyraliev TA, Sidorenko BA, Pataraia SA. [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part I. Ticlopidine]. Kardiologiia. 2009;49(4):72-83. Review. Russian. PubMed PMID: 19463124.

7: Zakarija A, Kwaan HC, Moake JL, Bandarenko N, Pandey DK, McKoy JM, Yarnold PR, Raisch DW, Winters JL, Raife TJ, Cursio JF, Luu TH, Richey EA, Fisher MJ, Ortel TL, Tallman MS, Zheng XL, Matsumoto M, Fujimura Y, Bennett CL. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb;(112):S20-4. doi: 10.1038/ki.2008.613. Review. PubMed PMID: 19180126; PubMed Central PMCID: PMC3500614.

8: Tohgi H. [Ticlopidine]. Nihon Rinsho. 2006 Oct 28;64 Suppl 7:570-5. Review. Japanese. PubMed PMID: 17461207.

9: Kirichenko AA. [Mechanism of action and clinical use of ticlopidine]. Kardiologiia. 2006;46(4):75-80. Review. Russian. PubMed PMID: 16710210.

10: Ikeda U. [Anti-platelet drugs (aspirin, ticlopidine, etc)]. Nihon Rinsho. 2006 Apr;64(4):743-7. Review. Japanese. PubMed PMID: 16613193.

11: Wlazłowski R, Goch A, Goch JH. [Place of ticlopidine in antiplatelet treatment]. Pol Merkur Lekarski. 2005 Aug;19(110):131-5. Review. Polish. PubMed PMID: 16245416.

12: Yagi H. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine]. Rinsho Byori. 2005 Jul;53(7):630-8. Review. Japanese. PubMed PMID: 16104532.

13: Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr;31(2):174-83. Review. PubMed PMID: 15852221.

14: Jacobson AK. Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Pract Res Clin Haematol. 2004 Mar;17(1):55-64. Review. PubMed PMID: 15171957.

15: Baralis G, Steffenino G, Dellavalle A, La Scala E, Uslenghi E. [Should we use clopidogrel instead of ticlopidine in elective coronary angioplasty?]. Ital Heart J Suppl. 2003 Sep;4(9):766-70. Review. Italian. PubMed PMID: 14635395.

16: Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N, Fragopanagou E, Tiniakou M, Matsouka P, Zoumbos N. Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol. 2002 Sep;71(1):24-32. Review. PubMed PMID: 12221670.

17: Pizarro AE, Andrade RJ, García-Cortés M, Lucena MI, Pérez-Moreno JM, Puertas M, Sánchez-Martínez H, Montero JL, Durán JA, Jiménez M, Ruiz-Montero A, Soto-Conesa MJ, Rodrigo L, de Francisco R, Alcántara R, Camargo R. [Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature]. Rev Neurol. 2001 Dec 1-15;33(11):1014-20. Review. Spanish. PubMed PMID: 11785026.

18: Black C, Paterson KR. New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost? Adverse Drug React Toxicol Rev. 2001 Dec;20(4):277-303. Review. PubMed PMID: 11770173.

19: Ha-Duong NT, Dijols S, Macherey AC, Dansette PM, Mansuy D. Inhibition by ticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine. Adv Exp Med Biol. 2001;500:145-8. Review. PubMed PMID: 11764927.

20: Cosmi B, Rubboli A, Castelvetri C, Milandri M. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev. 2001;(4):CD002133. Review. PubMed PMID: 11687144.



Additional Information